Brian
Fahey

Most PhD students dream of publishing papers. Brian Fahey, halfway through his biomedical engineering doctorate at Duke, realized he wasn't one of them. The lab was fine. The research was fine. But fine wasn't fast enough. He wanted to build things that reached patients in five years, not fifty.

The Stanford Biodesign Innovation Program gave him the vocabulary for what he'd been feeling. It isn't a technology program - it's a problem-identification program. The insight: don't start with a technology and look for nails. Start with the clinical need and engineer backward. Fahey absorbed this like a doctrine. He's been practicing it ever since.

His PhD focused on novel ultrasound technologies - a detail that aged interestingly, given that he'd spend the next two decades implanting sensors into human hearts. The thread isn't obvious until you see it: he's always been obsessed with measuring what the body is doing from the outside - or in Adona Medical's case, from deep inside the left and right atria of a failing heart.

That impatience isn't recklessness - it's strategy. Fahey has articulated a clear philosophy about medical device development: be your own harshest critic. Identify your highest risk factors. Then figure out which of those is fastest to mitigate and start there. It's a framework that keeps companies from burning capital on elegant engineering while dodging the harder questions about reimbursement, market fit, and clinical endpoints.

"Investors often don't worry about the prototype," he's said. "They're worried about market risk or pricing or reimbursement." He doesn't fight this. He prepares for it.

In 2008, Brian Fahey co-founded Niveus Medical. The premise was unglamorous and important: patients who spend extended time in the ICU - sedated, immobile, intubated - suffer profound muscle atrophy. Getting them moving again, faster, matters enormously for recovery. Niveus built rehabilitation solutions to accelerate exactly that.

Tom Fogarty - the man who invented the Fogarty balloon catheter, one of the most consequential medical devices in history - became one of Fahey's first investors. Fogarty is the kind of mentor whose involvement signals something. He has seen enough companies succeed and fail to not waste his money.

Fahey ran Niveus the way few venture-backed companies are run: lean. Four rounds of capital, each at a higher valuation than the last. No sprawl. No premature hiring. Over a decade, Niveus delivered treatments to more than 10,000 patients across 20 hospitals in the United States. Then Stryker acquired it in 2017. Fahey had his exit. He didn't stop.

After Stryker, Fahey didn't take a victory lap. He moved through three roles in quick succession: Johnson & Johnson Innovation (drug-device combinations in oncology), Arrinex (a neuromodulation company targeting chronic rhinitis - also later acquired by Stryker), and then Shifamed as executive-in-residence. That last role was the setup. Shifamed is a Silicon Valley medtech incubator. It's where Adona Medical was born in December 2019.

"Successful companies are almost always enormous group efforts," Fahey has said. The post-Stryker circuit wasn't wandering - it was deliberate knowledge accumulation about what makes medical devices succeed or fail in markets far more complex than a laboratory ever reveals.

Heart failure affects roughly 64 million people worldwide. The heart's pressure balance between its two upper chambers - the left atrium and right atrium - goes wrong in complex, individualized ways. Standard treatments offer a fixed response to a condition that behaves differently in every patient.

Adona Medical's answer to this is, on paper, a shunt. A small device implanted between the left and right atria to regulate pressure. But describing it as "a shunt" is like describing a smartphone as "a phone." The Adona shunt integrates bi-atrial pressure sensors - live readings from inside both chambers. It features an adjustable lumen: the diameter can be altered post-implantation, between 5mm and 14mm, using a proprietary induction catheter that operates through the skin. No return surgery. No invasive adjustment procedure. A physician reviews the daily pressure readings, decides the shunt needs to be larger or smaller, and makes that change remotely.

The material enabling this is shape memory nitinol - an alloy that returns to a predetermined geometry when energized. Biocompatible insulation keeps the pressure sensors functional inside the body. The result is a device that is simultaneously diagnostic and therapeutic, adjustable and self-reporting.

Fahey was candid about what this kind of product requires to succeed: it must be transformational, not incremental. "We have to aim to be like 500% better than everything else," he told Medsider. In cardiovascular medicine, where the competition includes established surgical interventions, pharmacological regimens, and other interatrial shunt devices, the bar for "better" is precise and brutal.

Adona Medical initiated its first-in-human clinical study and completed enrollment - milestones that represented, in Fahey's own words, the culmination of years of focused development work. The company grew from a $2.5M seed round in 2019 to $95.5M in total capital, with 33 employees operating from Los Gatos, California.

In December 2025, Fahey stepped down as CEO. He described the transition with characteristic directness: it was time for another leader to guide the company through its next phases. He reflected on what had been built - from scratch - and expressed gratitude for being part of an "elite team that accomplished so much." Exactly the kind of sentence a capital-efficient operator writes when they know the hard work is finished and the scale-up belongs to someone else.